Q-Chuck Technologies Inc.(QTI), a biopharmaceutical company, was formed in order to develop carbohydrate antigen-based immunoadsorbent devices (columns) to improve the outcome of organ transplantation. The success of a transplant depends on the degree of compatibility between the organ donor and recipient, determined by matching tissue type (HLA compatibility), ABO blood type, and, in the case of heart transplants, organ size. QTI’s products are designed to remove circulating antibodies from transplant candidates to enable successful engraftment of otherwise incompatible organs.